Annual Retained Earnings
-$1.34 B
-$373.63 M-38.81%
December 31, 2023
Summary
- As of February 24, 2025, MDGL annual retained earnings is -$1.34 billion, with the most recent change of -$373.63 million (-38.81%) on December 31, 2023.
- During the last 3 years, MDGL annual retained earnings has fallen by -$910.83 million (-214.08%).
- MDGL annual retained earnings is now -2631.60% below its all-time high of -$48.92 million, reached on December 31, 2015.
Performance
MDGL Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Retained Earnings
-$1.74 B
-$106.96 M-6.54%
September 30, 2024
Summary
- As of February 24, 2025, MDGL quarterly retained earnings is -$1.74 billion, with the most recent change of -$106.96 million (-6.54%) on September 30, 2024.
- Over the past year, MDGL quarterly retained earnings has dropped by -$106.96 million (-6.54%).
- MDGL quarterly retained earnings is now -3462.51% below its all-time high of -$48.92 million, reached on December 31, 2015.
Performance
MDGL Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Retained Earnings Formula
Retained Earnings = Retained Earnings (start of the period) + Net Income − Dividends Paid
MDGL Retained Earnings Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -38.8% | -6.5% |
3 y3 years | -214.1% | -6.5% |
5 y5 years | -859.5% | -6.5% |
MDGL Retained Earnings Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -100.3% | at low | -161.2% | at low |
5 y | 5-year | -498.6% | at low | -680.7% | at low |
alltime | all time | -2631.6% | at low | -3462.5% | at low |
Madrigal Pharmaceuticals Retained Earnings History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | -$1.74 B(+6.5%) |
Jun 2024 | - | -$1.64 B(+10.2%) |
Mar 2024 | - | -$1.48 B(+11.0%) |
Dec 2023 | -$1.34 B(+38.8%) | -$1.34 B(+9.2%) |
Sep 2023 | - | -$1.22 B(+8.8%) |
Jun 2023 | - | -$1.13 B(+8.3%) |
Mar 2023 | - | -$1.04 B(+8.0%) |
Dec 2022 | -$962.66 M(+44.3%) | -$962.66 M(+9.8%) |
Sep 2022 | - | -$876.75 M(+10.2%) |
Jun 2022 | - | -$795.56 M(+9.8%) |
Mar 2022 | - | -$724.83 M(+8.6%) |
Dec 2021 | -$667.31 M(+56.8%) | -$667.31 M(+10.7%) |
Sep 2021 | - | -$602.76 M(+11.7%) |
Jun 2021 | - | -$539.66 M(+12.9%) |
Mar 2021 | - | -$478.01 M(+12.4%) |
Dec 2020 | -$425.46 M(+90.6%) | -$425.46 M(+16.1%) |
Sep 2020 | - | -$366.34 M(+18.8%) |
Jun 2020 | - | -$308.38 M(+18.9%) |
Mar 2020 | - | -$259.36 M(+16.2%) |
Dec 2019 | -$223.22 M(+60.3%) | -$223.22 M(+14.2%) |
Sep 2019 | - | -$195.48 M(+12.3%) |
Jun 2019 | - | -$174.05 M(+12.8%) |
Mar 2019 | - | -$154.35 M(+10.8%) |
Dec 2018 | -$139.27 M(+30.8%) | -$139.27 M(+9.0%) |
Sep 2018 | - | -$127.80 M(+7.1%) |
Jun 2018 | - | -$119.28 M(+5.7%) |
Mar 2018 | - | -$112.83 M(+6.0%) |
Dec 2017 | -$106.46 M(+41.4%) | -$106.46 M(+8.6%) |
Sep 2017 | - | -$98.02 M(+9.3%) |
Jun 2017 | - | -$89.65 M(+10.3%) |
Mar 2017 | - | -$81.31 M(+8.0%) |
Dec 2016 | -$75.31 M(+53.9%) | -$75.31 M(+11.5%) |
Sep 2016 | - | -$67.56 M(-90.6%) |
Jun 2016 | - | -$716.15 M(+0.5%) |
Mar 2016 | - | -$712.77 M(+1357.0%) |
Dec 2015 | -$48.92 M | -$48.92 M(-93.0%) |
Sep 2015 | - | -$695.71 M(+2.6%) |
Jun 2015 | - | -$678.08 M(+3.0%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2015 | - | -$658.28 M(+3.2%) |
Dec 2014 | -$637.57 M(+15.6%) | -$637.57 M(+3.3%) |
Sep 2014 | - | -$617.22 M(+3.3%) |
Jun 2014 | - | -$597.25 M(+3.9%) |
Mar 2014 | - | -$574.97 M(+4.3%) |
Dec 2013 | -$551.41 M(+19.6%) | -$551.41 M(+4.6%) |
Sep 2013 | - | -$527.25 M(+4.5%) |
Jun 2013 | - | -$504.74 M(+4.7%) |
Mar 2013 | - | -$481.95 M(+4.5%) |
Dec 2012 | -$461.22 M(+15.8%) | -$461.22 M(+4.1%) |
Sep 2012 | - | -$443.10 M(+3.5%) |
Jun 2012 | - | -$428.10 M(+3.5%) |
Mar 2012 | - | -$413.48 M(+3.8%) |
Dec 2011 | -$398.43 M(+13.5%) | -$398.43 M(+2.8%) |
Sep 2011 | - | -$387.69 M(+3.4%) |
Jun 2011 | - | -$374.95 M(+3.4%) |
Mar 2011 | - | -$362.45 M(+3.2%) |
Dec 2010 | -$351.05 M(+11.9%) | -$351.05 M(+2.6%) |
Sep 2010 | - | -$342.23 M(+3.1%) |
Jun 2010 | - | -$331.96 M(+2.8%) |
Mar 2010 | - | -$322.89 M(+3.0%) |
Dec 2009 | -$313.58 M(-20.1%) | -$313.58 M(+2.3%) |
Sep 2009 | - | -$306.55 M(-27.8%) |
Jun 2009 | - | -$424.67 M(+2.0%) |
Mar 2009 | - | -$416.17 M(+6.0%) |
Dec 2008 | -$392.67 M(+30.9%) | -$392.67 M(+7.1%) |
Sep 2008 | - | -$366.72 M(+7.7%) |
Jun 2008 | - | -$340.40 M(+7.1%) |
Mar 2008 | - | -$317.70 M(+5.9%) |
Dec 2007 | -$300.05 M(+26.8%) | -$300.05 M(+5.5%) |
Sep 2007 | - | -$284.53 M(+5.5%) |
Jun 2007 | - | -$269.65 M(+6.6%) |
Mar 2007 | - | -$252.91 M(+6.9%) |
Dec 2006 | -$236.56 M(+31.9%) | -$236.56 M(+5.6%) |
Sep 2006 | - | -$224.07 M(+25.0%) |
Dec 2005 | -$179.29 M(+62.4%) | -$179.29 M(+39.8%) |
Mar 2005 | - | -$128.28 M |
Dec 2004 | -$110.42 M(+71.2%) | - |
Dec 2003 | -$64.49 M | - |
FAQ
- What is Madrigal Pharmaceuticals annual retained earnings?
- What is the all time high annual retained earnings for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual retained earnings year-on-year change?
- What is Madrigal Pharmaceuticals quarterly retained earnings?
- What is the all time high quarterly retained earnings for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly retained earnings year-on-year change?
What is Madrigal Pharmaceuticals annual retained earnings?
The current annual retained earnings of MDGL is -$1.34 B
What is the all time high annual retained earnings for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual retained earnings is -$48.92 M
What is Madrigal Pharmaceuticals annual retained earnings year-on-year change?
Over the past year, MDGL annual retained earnings has changed by -$373.63 M (-38.81%)
What is Madrigal Pharmaceuticals quarterly retained earnings?
The current quarterly retained earnings of MDGL is -$1.74 B
What is the all time high quarterly retained earnings for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly retained earnings is -$48.92 M
What is Madrigal Pharmaceuticals quarterly retained earnings year-on-year change?
Over the past year, MDGL quarterly retained earnings has changed by -$106.96 M (-6.54%)